GSK — GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: GB
- Exchange: NYSE
- Employees: 68,629
- Website: https://www.gsk.com
Latest SEC filings for GSK
- 6-K — 2026-07-13
- 6-K — 2026-07-13
- 6-K — 2026-06-08
- 6-K — 2026-05-28
- 6-K — 2026-03-31
- 6-K — 2026-03-25
- 6-K — 2026-03-24
- 6-K — 2026-03-04
- 6-K — 2026-03-04
- 6-K — 2026-03-03
Latest GSK news
- — Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks Investment Research)
- — Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? (Zacks Investment Research)
- — Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for (Zacks Investment Research)
- — Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight (GlobeNewswire Inc.)
- — HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China (GlobeNewswire Inc.)
- — GSK wins approval of bepirovirsen for hepatitis B (seekingalpha_market)
- — CDC confirms third measles-related death for 2026 (seekingalpha_market)
- — GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth (Zacks Investment Research)
- — Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer (GlobeNewswire Inc.)
- — Could Investing $5,000 in D-Wave Quantum Stock Today Make You a Millionaire? (The Motley Fool)
Educational tool only — not investment advice.